Novellusdx

Novellusdx Develops Tumor-Specific Driver Mutations, Focusing on Simulating Tumor Testing for Targeted Therapeutic Drugs and Quantifying Their Efficacy, Monitoring the Carcinogenic Activity of Patient-Relevant Genes and Proteins, as well as Monitoring Carcinogenic Activity Before and After Drug Administration. It Aims to Develop Highly Selective Drugs for Functionally and Genomically Defined Cancer Patients, Measuring the Impact of Drugs or Drug Candidates on Specific Tumors, Particularly Based on Their Ability to Inhibit Signal Protein Upregulation into the Nucleus.